Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer

BACKGROUND. We have already reported on fixed-dose-rate gemcitabine (FDR-Gem) in advanced, inoperable pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) in the context of a formal phase II study; building on that experience, we have now expanded the study to reach a cumulative ac...

詳細記述

保存先:
書誌詳細
主要な著者: Milella, Michele, Gelibter, Alain J., Pino, Maria Simona, Bossone, Giandominik, Marolla, Paolo, Sperduti, Isabella, Cognetti, Francesco
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2010
主題:
Online Only
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227937/
https://ncbi.nlm.nih.gov/pubmed/20189980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2008-0135
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料